Anti-Claudin-4 [KM3900]

Name: Anti-Claudin-4 [KM3900]
SKU: Ab03415
Availability: InStock

Description:

Recombinant monoclonal antibody to Claudin-4. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma KM3900.

Clone Name:

KM3900

Published Application(s):

IP, neutralizing, therapeutic, FC

Published Species Reactivity:

Human

Products based on this clone:

{{heading}}

Please Select

Ab03415-23.0 Anti-Claudin-4 [KM3900]
Human
Rabbit IgG
Purified
Ships in 5-6 weeks

Ab03415-2.0 Anti-Claudin-4 [KM3900]
Human
Mouse IgG2a
Purified
Ships in 5-6 weeks

Ab03415-2.3 Anti-Claudin-4 [KM3900]
Human
Mouse IgG2a
Fc Silent™
Purified
Ships in 5-6 weeks

Ab03415-10.0 Anti-Claudin-4 [KM3900]
Human
Human IgG1
Purified
Ships in 5-6 weeks

Ab03415-10.3 Anti-Claudin-4 [KM3900]
Human
Human IgG1
Fc Silent™
Purified
Ships in 5-6 weeks

UniProt Accession Number of Target Protein: O14493

Alternative Name(s) of Target: CLDN4; Claudin 4; Clostridium perfringens enterotoxin receptor; CPE-R; CPE-receptor; Williams-Beuren syndrome chromosomal region 8 protein; FERM BP-10751
Immunogen: The original antibody was generated from BXSB mice immunized with pancreatic cancer cells.

Specificity: The antibody specifically recognizes the conformational structure and binds to extracellular loop 2 of CLDN4. The antibody does not react with denatured CLDN4 protein. The antibody does not cross react with CLDN3, 5, 6, and 9. Claudin-4 is a tetraspanin transmembrane protein of tight junction structure and is highly expressed in pancreatic and ovarian cancers.

Application Notes: Cell lysates were prepared from pancreatic cancer cells (Capan-2 and HPAF-II) and CLDN/CHO cells, and subjected to immunoprecipitation analysis. The antibody was shown to specifically precipitate CLDN4. This antibody detected CLDN4 expressed on CHO cells by flow cytometry. Furthermore, binding of the antibody was detected on CLDN4-expressing pancreatic and ovarian cancer cells, but not on negative cells. Moreover, the chimeric IgG1 (KM3934) version of the antibody was made and its antitumor efficacy was evaluated. KM3934 induced dose-dependent antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro, and significantly inhibited tumor growth in MCAS or CFPAC-1 xenograft SCID mice in vivo (Suzuki et al., 2009; PMID:19555390). The antibody strongly bound to the CLDN4 expressed in breast cancer cells, colorectal cancer cells and prostate cancer cells. The antibody inhibited the cell movement ability of CLDN4 expression cells. The antibody showed neutralizing activity for CLDN4 (US8076458).

Antibody first published in: Suzuki et al. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers Cancer Sci. 2009 Sep;100(9):1623-30. PMID:19555390
Note on publication: The original paper describes the generation and characterization of the antibody.